Metropolitan Life Insurance Company (MetLife)’s Quince Therapeutics QNCX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-29	Closed	-$73.1K	–	2590
2021 Q4	$73.1K	Buy	29 +3	+12%	+$18.3K	﹤0.01%	2621
2021 Q3	$481K	Hold	26	–	–	0.01%	1495
2021 Q2	$278K	Buy	26 +1	+4%	+$8.38K	﹤0.01%	1920
2021 Q1	$179K	Hold	25	–	–	﹤0.01%	2097
2020 Q4	$138K	Hold	25	–	–	﹤0.01%	2185
2020 Q3	$249K	Hold	25	–	–	﹤0.01%	1647
2020 Q2	$231K	Buy	25 +6	+32%	+$55K	﹤0.01%	1705
2020 Q1	$174K	Hold	19	–	–	﹤0.01%	1674
2019 Q4	$214K	Buy	+19	New	+$115K	﹤0.01%	1872

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s QNCX Position: Q1 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Quince Therapeutics (QNCX) in Q1 2022, closing a stake of 29 shares — an estimated $73.1K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in QNCX in Q4 2019 and held it in 9 quarters. The position peaked at $481K in Q3 2021. 85 funds tracked by Wall St. Rank hold QNCX as of Q1 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining Quince Therapeutics position as of Q1 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 29 Quince Therapeutics shares in Q1 2022, an estimated $73.1K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Quince Therapeutics in Q4 2019 and held it in 9 quarters.
Metropolitan Life Insurance Company (MetLife)'s Quince Therapeutics position peaked at $481K in Q3 2021.
85 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.